We previously showed that the MUC5B gene expression was elevated by phorbol 12-myristate 13-acetate (PMA) through an EGFR-independent Ras/MEKK1/JNK and P38 signaling-based transcriptional mechanism. In the current study we elucidated the molecular basis of this transcriptional regulation using promoter-reporter gene expression and chromatin immunoprecipitation (ChIP) assays with primary human bronchial epithelial cells that are cultured at the air-liquid interface. We have observed that PMA-induced MUC5B Word count of abstract: 238
INTRODUCTION
Respiratory mucus secretion is essential for protecting the lungs and airways from inhaled particles, hazardous chemicals and microorganisms (1) . In many diseases, such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease(2, 3), excessive mucus production impairs the mucociliary function, leading to respiratory compromise and, ultimately, death (4) . This mucus hyper-secretion is primarily caused by an increase in mucin gene expression.
At least 20 human mucin (MUC) genes have been identified. Among these, at least nine of them (MUC1, 2, 4, 5AC, 5B, 7, 8, 13 and 19) are expressed in human airways. The large, gel-forming mucins ዊ MUC5AC, MUC5B, and MUC2 ዊ have been identified immunochemically in secretions and bronchial washings from normal airways, while MUC5AC (5, 6), MUC5B (7-9), MUC8 (10) and MUC2 (7) have been identified in sputum samples and bronchial washings from patients with chronic airway diseases. Among them, MUC5B and MUC5AC are the most prominent mucins in the airway. Normally, MUC5AC expression is limited to surface goblet epithelial cells, while MUC5B is predominantly expressed in the mucous cells of submucosal glands (11) . MUC5B expression can also be detected, however, in the surface goblet cells of lung tissues, mostly, in diseased conditions. Our laboratory has shown the expression of glandular MUC5B in the lining airway epithelial cells with an ovalbumin-induced mouse asthma model (12) . A Similar trans-expression 4 phenomenon has also been seen in patients who suffered from emphysema and diffuse panbronchiolitis (13, 14) . This kind of aberrant trans-expressions was only observed with MUC5B, but not with MUC5AC, suggesting that there is a close relationship between MUC5B gene expression and airway diseases Phorbol 12-myristate 13-acetate (PMA), a protein kinase C (PKC) activator, has been used as a model inflammatory stimulant that can modulate a variety of cellular events, including gene transcription (15) , cell growth and differentiation (16) . PMA also plays a significant role in the induction of both MUC5AC and MUC2 gene expression in NCI-H292 and HM3 colon cell lines (15, 17) . In our previous study, we showed that PMA is a potent inducer for MUC5B expression in differentiated primary human bronchial epithelial cell cultures, as well as in two cell linesዊan immortalized normal bronchial epithelial cell line, HBE1, and a lung adenocarcinoma cell line, A549 (18). In contrast to the EGFR-dependent ERK signaling pathway responsible for PMA-induced MUC5AC expression, our signal transduction studies have demonstrated a persistent, EGFR-independent Ras/MEKK1/JNK and p38-mediated transcriptional mechanism for PMA-induced MUC5B expression with the above three airway epithelial cell systems. To further extend our study, we have examined the transcriptional mechanism involved in PMA-induced MUC5B expression. Transcriptional regulation of airway mucin genes is important for understanding the pathogenesis that leads to mucus overproduction in chronic airway diseases. Current literature data implicates the 5 involvement of NF-B (17), Sp1 and AP1 transcription factors in the up-regulation of MUC2 and MUC5AC expression (19, 20) . There is very little information, however, about which transcription factors are involved in MUC5B gene regulation.
In this study, we utilized the promoter-reporter gene expression and chromatin immunoprecipitation assays to show that Sp1 and its binding sites in the MUC5B 5'-flanking regions are involved in PMA-induced MUC5B expression using two cell types ዊ differentiated primary human bronchial epithelial cells (NHBE) and an immortalized normal bronchial epithelial cell line (HBE1). Sp1 is a member of the zinc finger transcription factor family, which also includes at least four other Sp transcription factors (21) . These transcription factors are involved in a variety of physiological processes and have been shown to be able to bind more than 1000 different promoters for transcriptional regulation (22) . The Sp proteins have several conserved domains, including N-terminal transcription activation domains and C-terminal zinc finger DNA-binding domains (23, 24) . Sp1 plays a role in transcription activation, transcription repression and basal transcriptional activity of both viral and cellular genes (23).
This report is not only the first that identified the regulatory role of Sp1 in PMAinduced MUC5B expression in human airway epithelial cells, but also shed light on our understanding of the molecular mechanism underlining the specificity of Sp1 and its posttranslationally modified forms and their different biological functions. 6 
MATERIALS AND METHODS

Cell culture
Normal human primary tracheobronchial epithelial cells (NHBE) were isolated from human bronchi and trachea obtained from organ donors or autopsies through the University Cell isolation and culture methods were carried out as described previously, with some modifications (26, 27) . NHBE cells (1 x 10 4 cells/cm 2 ) were plated on a Costar
Transwell chamber (25 mm) in Ham's F12/Dulbecco's modified Eagle's medium (DMEM)
(1:1) supplemented with insulin (5µg/ml), transferrin (5 µg/ml), epidermal growth factor (EGF) (10 ng/ml), dexamethasone (0.1 µM), cholera toxin (10 ng/ml), bovine hypothalamus extract (15 µg/ml) and bovine serum albumin (0.5 mg/ml) (28, 29 
Construction of MUC5B promoter-luciferase clones: deletion and site-directed mutagenesis constructs
The MUC5B 5'-flanking region (4,169 base pairs) -luciferase reporter construct was previously constructed in our laboratory (30) and was used for the MUC5B promoter study.
The clones containing systematically deleted MUC5B 5'-flanking region were generated by PCR amplification with pairs of primers bearing restriction sites KpnI and NheI at their 5' and 3' ends, respectively. The resulting DNA fragments were digested, resolved and extracted from agarose gels, then purified and re-cloned into a promoterless pGL3 vector at the same restriction enzyme sites. The clone pGL3-MUC5B(2.6Kb) extends from site -2561 to +6, pGL3-MUC5B(1.62Kb) from -1610 to +6, pGL3-MUC5B(1.14Kb) from -1136 to +6, pGL3-MUC5B(0.66 Kb) from -652 to +6 and pGL3-MUC5B(0.22 Kb) from -222 to +6. The smallest clone is pGL3-MUC5B(0.08Kb), which extends from -78 to +18. All clones were 9 sequenced on both strands for sequence verification.
Site directed mutagenesis of the Sp1 transcription factor-binding sites on the MUC5B promoter was carried out according to the manufacturer's protocol using the Transformer Site Directed Mutagenesis kit (BD Biosciences-Clontech, Mountain View, CA).
Briefly, a 4.17Kb pGL3-MUC5B luciferase reporter construct was used as a template.
Specific primers were designed to introduce mutations into the Sp1 binding sites, as detailed below: Selection primer: CGATAAGGGACCGTCGACCGATG; Mutagenic primers: Sp1-1m, CCACAGCCCCTAACCGAGAGCAAAC; Sp1-2m, GCTGCTGGGTTTGGGGGCGTCCTG; Sp1-3m, GCAGTG GTGGTTGGGGAGCTCCAG.
After synthesis, NruI restriction enzyme digestion was used for primary selection. Mutagenic plasmids were amplified by transformation using mutS71-18 E. coli. Mutated promoters were sequenced to confirm the inclusion of site-directed base changes and the exclusion of random mutations. Successfully mutated pGL3-MUC5BSp1-1m, pGL3-MUC5BSp1-2m and pGL3-MUC5BSp1-3m clones were generated. All clones were sequenced on both strands to verify the sequences. µg/ml transferrin, 20 ng/ml cholera toxin, and 15 µg/ml bovine hypothalamus extract. Cells were harvested for reporter assays after 24 hours of incubation. Luciferase activity was determined using Luclite (PerkinElmer, Wellesley, MA) and quantified in a luminometer. -galactosidase activities were assayed and read at OD 405 . For each transfection, relative luciferase activity was normalized to -galactosidase activity. In this report, only NHBE tansfections are shown.
Despite the historical difficulties expected for transfecting cells cultured at an air liquid interface, this method allowed us to obtain luciferase readings from transfected cells 10-100 times higher than the un-transfected control, the transfection efficiency is about 20%.
Nuclear extract preparation and NoShift TM transcription factor assay
The nuclear extracts from NHBE or HBE1 cells cultured for two weeks in retinoic acid-supplemented media at an air liquid interface were prepared according to the GCTCCAGCCACGTGTGTT.
Inhibitor studies
For the inhibitor studies, NHBE and HBE1 cells were cultured in retinoic acid (RA)ዊsupplemented media at an air-liquid interface for two weeks and then starved for one day in medium containing no supplement except RA. After the starvation period, cells were pre-treated with mithramycin A or vehicle for one hour prior to PMA treatment. RNA and protein extracts were prepared from these cultures 24 hours after PMA treatment for real-time
RT-PCR and luciferase quantification, respectively. For the reporter gene activity assay, cells
were transfected with pGL3-MUC5B following the inhibitor treatments.
Mithramycin A, purchased from Sigma (Sigma-Aldrich, Saint Louis, MO), was used at dose ranges based on the manufacturer's suggestion. The toxicity towards our cultured cells was negligible, as observed by the trypan blue exclusion test.
Immunoprecipitation and western blot analysis
NHBE cells were cultured in retinoic acid (RA)ዊsupplemented media at an air-liquid interface for two weeks and then starved for 1 day in medium containing no supplement except RA. Cells were then treated with vehicle or 10 nM PMA for 24 hours before being lysed in RIPA buffer (1% NP-40; 0.5% deoxycholic acid; 1 mM EDTA; 150 mM NaCl; 50 13 mM Tris-HCl; pH8.0, 1 mM PMSF; 1 mM sodium orthovanadate; 1 mM NaF; 1 µg/ml aprotinin; 1 µg/ml leupeptin; 1 µg/ml pepstain). Phosphorylated Sp1 was immunoprecipitated using anti-phospho-serine antibody conjugated agarose (Sigma-Aldrich, Saint Louis, MO).
Eight hundred micrograms of lysate was incubated with 50 µl agarose at 4 ዊ C overnight.
Immunoprecipitated complexes were subjected to electrophoresis on an SDS / 10% polyacrylamide gel and transferred to a PVDF membrane (BioRad Laboratories, Hercules, CA). Sp1 was detected using Sp1 polyclonal antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA).
Chromatin immunoprecipitation (ChIP) assays
NHBE cells were cultured in retinoic acid (RA)ዊsupplemented media at an air-liquid interface for two weeks and then starved for one day in medium containing no supplement except RA.
After the starvation period, cells were treated with vehicle or 10 nM PMA for 24 hours. ChIP assays were performed using the chromatin immunoprecipitation assay kit (Millipore, 
Statistical analysis
Experiments were carried out in triplicate and at least in two independent cultures.
Representative data from these independent cultures are presented. Significance of the difference in means between treated and control samples were determined by student's t test, P < 0.05 is considered as a significant difference.
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RESULTS
PMA stimulates MUC5B mucin production
We previously showed that PMA induced both MUC5B mRNA and protein synthesis in primary NHBE, HBE1 and A549 cells (1) . In this study, we examined whether the induction is time-and dose-dependent. As shown in Fig. 1 , using primary NHBE cells maintained under air-liquid interface conditions, PMA induced MUC5B mRNA in a doseand time-dependent manner ( Fig. 1A and 1B, respectively), whereas 4 -PMA, a negative control for phorbol ester, failed to elicit any induction. Induction was seen at PMA levels as low as 2 nM. More than 2-fold induction was seen 16 hrs after PMA treatment and the induction reached to more than 3-fold 48 hrs after PMA treatment. These results confirm that PMA, a protein kinase C activator, is a potent stimulator for MUC5B gene expression in cultured human airway epithelial cells.
Deletion analysis of PMA-induced MUC5B promoter activity
Systematically deleted MUC5B 5'-flanking regions spanning from +6 bp to -4169 bp, 2561bp, 1610bp, 1136bp, -652bp, 222bp and -78 bp relative to the transcription initiation site ( Fig. 2A) were generated and cloned into the promoterless pGL3 vector. Those (Fig. 3B ).
To further confirm that Sp1 binding is directly involved in the regulation of MUC5B gene transcription, NHBE cells were pretreated with mithramycin A to inhibit Sp1 binding. A dose-dependent inhibition of MUC5B promoter activity was observed (Fig. 3C ). With 0.1 µM mithramycin A, there was 30% inhibition of PMA-induced promoter activity with no change in the basal promoter activity. At 1µM mithramycin A, however, there was a significant reduction of PMA-induced activity, in addition to the abrogation of basal promoter activity.
The reduction in basal promoter activity is not due to toxicity, since no apparent cell death was detected at this dose according to the trypan blue dye-exclusion assay (unpublished data).
Similar results were seen in HBE1 cells (right panel of Fig. 3C ), suggesting the involvement of a Sp1-based transcriptional mechanism in the regulation of both basal and PMA-induced MUC5B gene expression.
Sp1 phosphorylation is activated by PMA treatment
Since phosphorylation has been implicated in changes of Sp1 transcriptional activity (33, 34), we asked whether PMA stimulated Sp1 phosphorylation using immunoprecipitation with whole protein lysates of NHBE cells with or without PMA treatment. Because phosphorylation of Sp1 is predominantly on serine residues, with less than 5% on threonine 18 and none on tyrosine (35) , the phosphorylated form of Sp1 was immunoprecipitated with anti-phospho-serine antibody -conjugated agarose, followed by western blot analyses with anti-Sp1 antibody. Simultaneously, non-immunoprecipitated samples were loaded on the same gel and probed with anti-Sp1 antibody to allow for protein normalization ( Fig. 4 ; lower panel). As shown in Fig. 4 , PMA treatment significantly enhanced the phosphorylation of Sp1, suggesting that PMA can activate Sp1 transcriptional activity through serine phosphorylation.
Characterization of putative Sp1 sites by NoShift TM transcriptional factor assay and site-directed mutagenesis
To further characterize the putative Sp1 sites that are important in the regulation of MUC5B expression, we examined the two MUC5B putative Sp1 sequences situated in the critical -222 to -78 region, and a third Sp1 site located at -458/-437 bp with lysates obtained from PMA treated and untreated cells. PMA treated lysates induced a more than 3-fold increase in cis-/ trans-Sp1 binding when compared to the untreated samples (Fig. 5A ). Both basal and PMA-induced Sp1 binding were completely blocked in a competition assay with a 50-fold molar excess (500 pM) of wild type synthetic Sp1-1, Sp1-2, and Sp1-3 oligomers.
However, the mutated form of those putative Sp1 cis elements, Sp1-1m, Sp1-2m and Sp1-3m, failed to compete, indicating that the specific mutated base pairs on Sp1-1m, Sp1-2m and Sp1-3m (upper panel of Fig. 5A ) are critical for Sp1 binding.
Based on the above mutated Sp1 sequences, three Sp1-specific mutants were generated in the pGL3-MUC5B (4.17 Kb) clone and are named as pGL3-MUC5BSp1-1m, pGL3-MUC5BSp1-2m and pGL3-MUC5BSp1-3m. Plasmid DNAs obtained from these three mutants and the wild type pGL3-MUC5B were used to transfect NHBE cells. As shown in does not appear to be involved in either the basal or the PMA-induced MUC5B transcription activity. These results agree with the deletion analysis (Fig. 2) .
Demonstration of Sp1 binding to MUC5B promoter in situ by ChIP assay
To determine if PMA-induced MUC5B promoter activity is due to altered interactions between Sp1 and MUC5B promoter DNA, the effects of PMA on the binding of activity. Therefore, SP1-1 is responsible for the basal activity of MUC5B promoter, and the PMA-induced MUC5B promoter activity is due to the increased binding on Sp1-2. However, this induction can only happen when the basal activity is fulfilled. In a separate study with regular PCR rather than the real-time PCR, a similar result was also observed (Fig. 6B) 22
DISCUSSION
Extensive work has been done to elucidate the molecular mechanism of MUC5AC and MUC2 gene expression (16, 18, 20, 36) , but studies on the regulation of MUC5B gene expression are scarce. In this paper, we examined the molecular mechanism of MUC5B gene expression in human airway epithelial cells using a potent PKC activator, PMA.
Under PMA treatment, MUC5B gene expression was enhanced in a time-and dosedependent manner (Fig 1) . This effect of PMA appeared to be at the transcriptional level, since the elevation pattern of MUC5B promoter-reporter activity was similar to the elevation pattern of MUC5B mRNA and protein resulting from PMA-treated NHBE cells sites on the MUC5B promoter in NHBE and HBE1 cells by ChIP assays. These interactions occurred with both the basal and the PMA-induced conditions. These findings are consistent with the notion that MUC5B, like other mucin genes, is regulated by a Sp1-dependent transcriptional mechanism (16, 20) . Similar results were reported in colon cancer cells and gastric carcinoma cancer cell lines (31) . In gastric carcinoma cells,
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MUC5B expression was governed by a proximal promoter as well as a highly active distal promoter with a TATA-like sequence located at 1142/ 1134 (TAAATAAAA) (31) . In our study of NHBE and HBE1 cells, the 5'-flanking region in the vicinity of the distal TATA box appeared to have no effect on MUC5B gene expression, as suggested by our deletion study in Fig. 2 .
Sp1 is a member of a multigene family that binds DNA through COOH-terminal zinc-finger motifs (37) . Although Sp1 activity was initially thought to be constitutive, it has since been shown to be regulated at different levels (38) . Sp1 can be O-glycosylated, which affects its turnover (39) . Sp1 can also be phosphorylated at several amino acid residues under various circumstances by a variety of kinases (40) . Phosphorylated Sp1 has been reported to up-or down-regulate gene transcription (41, 42) . It has been shown that a change in the level of Sp1 phosphorylation results in altered DNA-binding activity in various genes (43) (44) (45) . Here, we show that PMA treatment induces Sp1 phosphorylation (Fig. 4) , which increases the DNA-binding activity of Sp1 to the MUC5B promoter and then increases MUC5B mucin expression.
While a significant role of Sp1 in the transcriptional regulation of other mucin genes has been reported (16, (46) (47) (48) (49) , the physical interaction and functionality of the Sp1-binding sites in these mucin genes were not clear. Here, we have identified two proximal Sp1 binding sites: Sp1-1 and Sp1-2, located at -122/-114 and -196/-184 bp, respectively, on the human MUC5B promoter region as the important regulators for basal and PMAenhanced promoter activities in human airway epithelial cells. Site-directed mutagenesis studies and Chip assays indicated that Sp1-1 is pivotal for basal activity of the MUC5B
promoter, while the Sp1-2 site is needed for PMA-induced MUC5B expression (Fig. 5B) . 24 Although the third Sp1 site (Sp1-3, at -458/-437) can bind Sp1 transcription factor in the cell-free NoShift TM transcription factor assay, as well as the Chip assay, mutation at this site showed no effect on MUC5B promoter activity. These results are consistent with our deletion study, indicating that the promoter region affecting PMA-induced MUC5B expression is limited to the region of -222/-78 bp relative to the transcriptional start site (Fig. 2B) . 
